Correll, Christoph U. http://orcid.org/0000-0002-7254-5646
Kim, Edward http://orcid.org/0000-0001-8247-6675
Sliwa, Jennifer Kern http://orcid.org/0000-0002-4567-096X
Hamm, Wayne http://orcid.org/0000-0001-5213-5095
Gopal, Srihari http://orcid.org/0000-0001-5254-2192
Mathews, Maju http://orcid.org/0000-0003-4144-1008
Venkatasubramanian, Raja http://orcid.org/0000-0003-2764-0254
Saklad, Stephen R. http://orcid.org/0000-0002-6181-138X
Funding for this research was provided by:
Janssen Research and Development
Article History
Accepted: 23 November 2020
First Online: 28 January 2021
Declarations
:
: Open Access was funded by Janssen Global Services, LLC. This work was sponsored by Janssen Research and Development, LLC. Janssen Research and Development and Scientific Affairs, LLC reviewed the manuscript.
: SRS is an employee of The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division. He was appointed to the Texas Health and Human Services Commission, San Antonio State Hospital and the UT Health San Antonio, Long School of Medicine; has been a consultant for Alkermes, Intra-Cellular Therapies, Genomind, Karuna, and Otsuka; has participated in speakers bureaux for Alkermes, Intra-Cellular Therapies, Neurocrine, and Teva; has served as speaker for several professional organizations; has been on the Business Development Council for the College of Psychiatric and Neurologic Pharmacists; was the Treasurer (term ended 2019) for the College of Psychiatric and Neurologic Pharmacists Foundation; and has served as an expert witness on both defendant and plaintiff sides. He has no direct stock ownership in pharmaceutical corporations. CUC has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka; served on a data safety monitoring board for Lundbeck, Rovi, Supernus, and Teva; received grant support from the Berlin Institute of Health, Janssen, the National Institute of Mental Health, the Patient-Centered Outcomes Research Institute, Takeda, and the Thrasher Foundation; and received royalties from UpToDate. He is also a stock option holder of LB Pharma. JKS, SG, MM, WH, and RV are employees and shareholders of Johnson & Johnson. EK is a former employee and shareholder of Johnson & Johnson.
: Not applicable.
: Not applicable.
: Not applicable.
: The data-sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access Project site at ExternalRef removed.
: Not applicable.
: All authors contributed to the design of the search algorithm, to the analysis of the results and to the writing of the manuscript. All authors approved the final version of this manuscript. Conceptualization: CUC, EK (lead), JKS, WH, MM, RV, SRS. Methodology: CUC, EK, JKS, WH, SG, MM, SRS. Formal analysis and investigation: EK, MM. Writing – original draft preparation: EK, JKS, SG, MM. Writing – review and editing: CUC, EK, JKS, WH, SG, MM, RV, SRS. Funding acquisition: EK (lead), MM. Resources: EK (lead), MM. Data curation: EK, JKS, WH, MM. Supervision: CUC, EK (lead), MM, SRS. Investigation: EK, SG, MM. Project administration: EK, MM. Software: EK, MM. Validation: EK, MM. Visualization: EK, MM, RV, SRS.